| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Gene (GSTP1) CpG Island Is Present in a Subset of Proliferative Inflammatory Atrophy Lesions but Not in Normal or Hyperplastic Epithelium of the Prostate









From the Department of Pathology,*the Brady Urological Institute,
the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
and the Bloomberg School of Public Health,
the Johns Hopkins Medical Institutions, Baltimore, Maryland
Somatic inactivation of the glutathione S-transferase-
gene (GSTP1) via CpG island hypermethylation occurs early during prostate carcinogenesis, present in
70% of high-grade prostatic intraepithelial neoplasia (high-grade PIN) lesions and more than 90% of adenocarcinomas. Recently, there has been a resurgence of the concept that foci of prostatic atrophy (referred to as proliferative inflammatory atrophy or PIA) may be precursor lesions for the development of prostate cancer and/or high-grade PIN. Many of the cells within PIA lesions contain elevated levels of GSTP1, glutathione S-transferase-
(GSTA1), and cyclooxygenase-II proteins, suggesting a stress response. Because not all PIA cells are positive for GSTP1 protein, we hypothesized that some of the cells within these regions acquire GSTP1 CpG island hypermethylation, increasing the chance of progression to high-grade PIN and/or adenocarcinoma. Separate regions (n =199) from 27 formalin-fixed paraffin-embedded prostates were microdissected by laser-capture microdissection (Arcturus PixCell II). These regions included normal epithelium (n = 48), hyperplasticepithelium from benign prostatic hyperplasia nodules (n = 22), PIA (n = 64), high-grade PIN (n = 32), and adenocarcinoma (n = 33). Genomic DNA was isolated and assessed for GSTP1 CpG island hypermethylation by methylation-specific polymerase chain reaction. GSTP1 CpG island hypermethylation was not detected in normal epithelium (0 of 48) or in hyperplastic epithelium (0 of 22), but was found in 4 of 64 (6.3%) PIA lesions. The difference in the frequency of GSTP1 CpG island hypermethylation between normal or hyperplastic epithelium and PIA was statistically significant (P = 0.049). Similar to studies using nonmicrodissected cases, hypermethylation was found in 22 of 32 (68.8%) high-grade PIN lesions and in 30 of 33 (90.9%) adenocarcinoma lesions. Unlike normal or hyperplastic epithelium, GSTP1 CpG island hypermethylation can be detected in some PIA lesions. These data support the hypothesis that atrophic epithelium in a subset of PIA lesions may lead to high-grade PIN and/or adenocarcinoma. Because these atrophic lesions are so prevalent and extensive, even though only a small subset contains this somatic DNA alteration, the clinical impact may be substantial.
This article has been cited by other articles:
![]() |
H. Uemura, H. Ishiguro, Y. Ishiguro, K. Hoshino, S. Takahashi, and Y. Kubota Angiotensin II Induces Oxidative Stress in Prostate Cancer Mol. Cancer Res., February 1, 2008; 6(2): 250 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Bethel, D. Faith, X. Li, B. Guan, J. L. Hicks, F. Lan, R. B. Jenkins, C. J. Bieberich, and A. M. De Marzo Decreased NKX3.1 Protein Expression in Focal Prostatic Atrophy, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma: Association with Gleason Score and Chromosome 8p Deletion. Cancer Res., November 15, 2006; 66(22): 10683 - 10690. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S Perry, R. Foley, K. Woodson, and M. Lawler The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 357 - 377. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Umetani, M. F.G. de Maat, E. Sunami, S. Hiramatsu, S. Martinez, and D. S.B. Hoon Methylation of p16 and Ras Association Domain Family Protein 1a during Colorectal Malignant Transformation Mol. Cancer Res., May 1, 2006; 4(5): 303 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yegnasubramanian, X. Lin, M. C. Haffner, A. M. DeMarzo, and W. G. Nelson Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation Nucleic Acids Res., February 9, 2006; 34(3): e19 - e19. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Henrique, C. Jeronimo, M. R. Teixeira, M. O. Hoque, A. L. Carvalho, I. Pais, F. R. Ribeiro, J. Oliveira, C. Lopes, and D. Sidransky Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis Mol. Cancer Res., January 1, 2006; 4(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Lee, S. Yegnasubramanian, X. Lin, and W. G. Nelson Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1 J. Biol. Chem., December 9, 2005; 280(49): 40749 - 40756. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kim, J. Lapointe, G. Kaygusuz, D. E. Ong, C. Li, M. van de Rijn, J. D. Brooks, and J. R. Pollack The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer Cancer Res., September 15, 2005; 65(18): 8118 - 8124. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Palapattu, S. Sutcliffe, P. J. Bastian, E. A. Platz, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Prostate carcinogenesis and inflammation: emerging insights Carcinogenesis, July 1, 2005; 26(7): 1170 - 1181. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Bastian, G. S. Palapattu, X. Lin, S. Yegnasubramanian, L. A. Mangold, B. Trock, M. A. Eisenberger, A. W. Partin, and W. G. Nelson Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy Clin. Cancer Res., June 1, 2005; 11(11): 4037 - 4043. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. K.Y. Chan, U.-S. Khoo, K. Y.K. Chan, H. Y.S. Ngan, S.-S. Li, P.-M. Chiu, L.-S. Man, P. P.C. Ip, W.-C. Xue, and A. N.Y. Cheung Promoter Methylation and Differential Expression of {pi}-Class Glutathione S-Transferase in Endometrial Carcinoma J. Mol. Diagn., February 1, 2005; 7(1): 8 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jeronimo, R. Henrique, M. O. Hoque, E. Mambo, F. R. Ribeiro, G. Varzim, J. Oliveira, M. R. Teixeira, C. Lopes, and D. Sidransky A Quantitative Promoter Methylation Profile of Prostate Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8472 - 8478. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jeronimo, R. Henrique, M. O. Hoque, F. R. Ribeiro, J. Oliveira, D. Fonseca, M. R. Teixeira, C. Lopes, and D. Sidransky Quantitative RAR{beta}2 Hypermethylation: A Promising Prostate Cancer Marker Clin. Cancer Res., June 15, 2004; 10(12): 4010 - 4014. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Shappell, G. V. Thomas, R. L. Roberts, R. Herbert, M. M. Ittmann, M. A. Rubin, P. A. Humphrey, J. P. Sundberg, N. Rozengurt, R. Barrios, et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Cancer Res., March 15, 2004; 64(6): 2270 - 2305. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |